A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).

Tomoaki MoriokaMasakazu TakeuchiAkichika OzekiMasanori Emoto

Published in: Diabetes, obesity & metabolism (2024)

Dulaglutide 1.5 mg once weekly demonstrated superior glycaemic control versus dulaglutide 0.75 mg once weekly, with comparable safety and tolerability, in Japanese people with T2D.

Keyphrases

double blind
phase iii
placebo controlled
clinical trial
phase ii
open label
study protocol
type diabetes